Peringkat dalam Saham
#36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Harga Saham
$0.30221445
Terakhir disinkronkan: 2023-05-22
Kapitalisasi Pasar
$2.49M
Perubahan (1 hari)
-0.10%
Perubahan (1 tahun)
0.00%
Perdagangan Lysogene S.A. (LYS)
Harga LYS dengan kapitalisasi pasar B
Kapitalisasi pasar dari Lysogene S.A.(LYS)
Kapitalisasi Pasar: $2.49M
Per August 2026, Lysogene S.A. memiliki kapitalisasi pasar sebesar $2.49M. Ini menjadikan Lysogene S.A. sebagai perusahaan 36618th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Lysogene S.A. dari 2017 hingga 2026
LYS dibandingkan dengan 5 teratas stocks paling populer
| Harga LYS |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.452T
|
+218,595,217.06%
|
|
|
|
|
$4.490T
|
+180,029,466.10%
|
|
|
|
|
$4.162T
|
+166,893,655.77%
|
|
|
|
|
$3.676T
|
+147,404,657.49%
|
|
|
|
|
$2.833T
|
+113,592,136.88%
|
